Josh Distler, J.D.

Chief Executive Officer

Josh Distler, JD, has extensive experience building and investing in biotechnology companies. Prior to joining Oak Hill Bio, Mr. Distler served as a senior member of the investment team and Head of Crossover and Quantitative Equity at Athanor Capital, a global investment firm. Before Athanor Capital, Mr. Distler was the Managing Director, Portfolio Manager, and Head of Portfolio Research at Magnitude Capital. He has also worked as Chief Operating Officer of Global Private Investing at D. E. Shaw & Co., Chief Operating Officer at Attenuon, a cancer drug development firm, and Director of Schrödinger, Inc., a leader in physics-based molecular modeling for drug design. Mr. Distler received his JD from Yale Law School and his bachelor’s in Economics from Harvard University.